Seaport reports GlyphAgo Phase 1 data with 6.8-fold bioavailability gain
+1 new source since this summary was written
Seaport Therapeutics presented first-stage clinical pharmacokinetic findings for GlyphAgo at the 39th European College of Neuropsychopharmacology Congress in Munich. The oral prodrug produced a 6.8-fold increase in agomelatine bioavailability versus the unmodified drug in a study of 174 healthy volunteers. Seaport has begun a Phase 2a study, expects its initial readout in early 2028, and plans to start a Phase 2/3 trial in the first half of 2027.
Why it matters
The disclosure advances GlyphAgo from Phase 1 into testing for generalized anxiety disorder and sleep disturbance. The reported results cover drug exposure and absorption, so they do not establish efficacy or safety in later-stage patients.
Key facts
- 1The Phase 1 program enrolled 174 healthy volunteers. investing.com
- 2GlyphAgo increased agomelatine bioavailability 6.8-fold compared with unmodified agomelatine. investing.com
- 3Seaport has initiated a Phase 2a trial, with topline results expected in early 2028, and plans to begin a Phase 2/3 trial in the first half of 2027. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.